We found that phosphorylation of NF-κB at T505 was increased by PAM or PAM/TRAIL treatment (Figure 6a), suggesting the possibility that PAM or PAM/TRAIL may suppress migration and proliferation of cancer cells via inhibition of NF-κB signal pathway. The gene discussed is NFKB1; the disease is cancer.